A clinical stage US/based biotech (not Big Pharma) built on “[d]eveloping next-generation therapies with proven mechanisms of action and best-in-class potential to transform the treatment of severe autoimmune diseases” licenses a drug developed by a Chinese biotech 👀 🐂 or 🐻

Boston Children's Hospital, along with Broad Clinical Labs and Roche Sequencing Solutions, has demonstrated that rapid genomic sequencing and interpretation are achievable in a matter of hours! medicalxpress.com/news/2025-10-w…

Cool to see actual Nobel Prize medals at the Mayo Clinic “for their discoveries relating to the hormones of the adrenal cortex, their structure and biological effects”

“Takeda and Innovent will co-develop IBI363 globally with a 60/40 (Takeda/Innovent) cost split and co-commercialize it in the U.S. with a 60/40 (Takeda/Innovent) profit or loss split.”

Chris Garabedian Brian Skorney Sam Fazeli Bruce Booth John Maraganore 🇺🇸🇬🇷🇺🇦 Daphne Zohar Paul Matteis Brad Loncar michal preminger Grace E. Colón, Ph.D. (she/her/they) Tess Cameron Tim Opler On $TAK and $IVBXF, Sam Fazeli summarizes that: “It’s a global co-commercialization and co-development deal. So that's pretty interesting. I haven't seen too many examples. That is where the Chinese partner keeps some of the rights. Particularly they highlight the U.S. side of

Looking forward to connecting with everyone at Biocom California's Greater LA CEO Summit on October 29. #BiocomCEOSummit app.sosha.ai/s/YqNDXeSc

Another SD biotech cc:Rich Law

We are building an aggressively capital efficient, clinical execution focused, biotech startup - with a feature/goal of zero headcount G&A (i.e. automated/AI) - finding solutions for this has been disappointingly hard despite all the social media/techcrunch noise from

Daphne Zohar Bruce Booth Sam Fazeli Brian Skorney Yaron Werber Eric Schmidt michal preminger John Maraganore 🇺🇸🇬🇷🇺🇦 Paul Matteis Dawn Bell Grace E. Colón, Ph.D. (she/her/they) Tim Opler On evaluating CEOs, Bruce Booth warns against celebrity worship as he discusses in Part 2 of his trilogy on his 20 years in early-stage biotech. “There are a lot of really exceptional leaders in our field who've rolled the dice a couple times, and it takes six to eight years to

BD deal held up? 👇🏼

$QURE & other FDA uncertainty aside, reasons to love biotech from Stifel: M&A strongest since 2019, money flowing back, risk on sentiment returning. Re valuations, ph1 & ph2 back to peak values, ph3 beyond peak. Preclinical way below. BTW, $XBI performance post policy headwind

With macro uncertainty for large BioPharma settling out, FTC risk coming down, P/E valuations at long term lows, huge LoE's ahead... it's time for some Big-Big M&A once again. My take: we will see one or more >$50B biopharma acquisition within the Top 20 players in the next

👇🏼trade secrets, [know-how], and speed wins the day, even in biotech/techbio - also don’t publish (many have said this) unless absolutely and unequivocally mission critical - and obviously not for vanity and prestige.

Mark Cuban is trying to shake up biosimilar pricing, dramatically undecutting not just J&J’s big-selling Stelara drug but the biosimilars, too -- by a lot. By Elaine Chen and pharmalot statnews.com/pharmalot/2025…

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer prnewswire.com/news-releases/…

The Population Health team (led by Clive) has an unassailable track record of value creation and ROI.

This is the 2nd mainstream tech podcast Eli Lilly and Company CEO Dave Ricks has done in the past month or so (he also went on The All-In Podcast). He’s really the first Pharma CEO I can think of who has broken into the mainstream zeitgeist. Great ambassador for the field and hopefully a

From 2013 to 2022, AbbVie poured a total of $1.75 billion into the Calico collaboration . . . fiercebiotech.com/biotech/abbvie…

Why is Draper Associates doubling down on investing in bio? Why now? The world is finally transitioning from chemotherapy to bio-cures. Entrepreneurs and scientists today are working to completely cure and eliminate disease, rather than giving patients chronic treatments and just